Metagenomi (MGX) Stock Price, News & Analysis

Company Overview

Metagenomi, Inc. is a biotechnology company developing genetic medicines using genome-editing technologies discovered through metagenomic research. The company searches genetic material from diverse microorganisms to identify naturally occurring editing systems and combines these discoveries with machine-learning tools to develop potential therapies.

Its research platform is designed to support the development of genome-editing medicines for a range of diseases, including programs intended to make precise changes to DNA in human cells. Metagenomi’s product candidates and discovery efforts have focused on both in vivo and ex vivo applications, although the status and scope of individual programs may change as the company advances its research pipeline.

Founded in 2018, Metagenomi is headquartered in Emeryville, California, and has pursued collaborations and strategic relationships with larger life-sciences companies to support the development and potential commercialization of its technologies. The company was co-founded by Brian C. Thomas, Ph.D., who has served as its chief executive officer. Metagenomi began trading publicly on the Nasdaq under the symbol MGX in 2024.

Key Stats

• Today's Range: $1.02 to $1.10
• 50-Day Range: $1.02 to $1.24
• 52-Week Range: $1.02 to $3.95
• Volume: 121,801 shs
• Average Volume: 139,558 shs
• Market Capitalization: $38.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Moderate Buy

Metagenomi Stock Analysis - MarketRank™

Metagenomi scored higher than 69% of companies evaluated by MarketBeat, and ranked 219th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Metagenomi has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Metagenomi has a consensus price target of $6.00, representing about 488.2% upside from its current price of $1.02.

Amount of Analyst Coverage

Metagenomi has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Metagenomi are expected to grow in the coming year, from ($2.50) to ($1.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Metagenomi is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Metagenomi is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Metagenomi has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.33% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 7.31.

Change versus previous month

Short interest in Metagenomi has recently decreased by 0.35%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Metagenomi does not currently pay a dividend.

Dividend Growth

Metagenomi does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Metagenomi this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for MGX on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $23,400.00 in company stock, which represents 0.0607% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Metagenomi insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Metagenomi has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MGX
• Previous Symbol: NASDAQ:MGX
• CIK: 1785279
• Web: www.metagenomi.co
• Phone: 510-871-4880
• Fax: N/A
• Employees: 113
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Metagenomi: $6.00
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +488.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$87.87 million
• Net Margins: -384.61%
• Pretax Margin: -690.60%
• Return on Equity: -63.65%
• Return on Assets: -44.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.50
• Quick Ratio: 4.50

Sales & Book Value

• Annual Sales: $13.56 million
• Price / Sales: 2.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.22 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 37,777,000
• Free Float: 33,055,000
• Market Cap: $38.53 million
• Optionable: N/A
• Beta: 0.69